

## § 862.3880

use or abuse and in monitoring levels of cannabinoids during clinical investigational use.

(b) *Classification*. Class II.

## § 862.3880 Theophylline test system.

(a) *Identification*. A theophylline test system is a device intended to measure theophylline (a drug used for stimulation of the muscles in the cardiovascular, respiratory, and central nervous systems) in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of theophylline overdose or in monitoring levels of theophylline to ensure appropriate therapy.

(b) *Classification*. Class II.

## § 862.3900 Tobramycin test system.

(a) *Identification*. A tobramycin test system is a device intended to measure tobramycin, an aminoglycoside antibiotic drug, in plasma and serum. Measurements obtained by this device are used in the diagnosis and treatment of tobramycin overdose and in monitoring levels of tobramycin to ensure appropriate therapy.

(b) *Classification*. Class II.

## § 862.3910 Tricyclic antidepressant drugs test system.

(a) *Identification*. A tricyclic antidepressant drugs test system is a device intended to measure any of the tricyclic antidepressant drugs in serum. The tricyclic antidepressant drugs include imipramine, desipramine, amitriptyline, nortriptyline, protriptyline, and doxepin. Measurements obtained by this device are used in the diagnosis and treatment of chronic depression to ensure appropriate therapy.

(b) *Classification*. Class II.

## § 862.3950 Vancomycin test system.

(a) *Identification*. A vancomycin test system is a device intended to measure vancomycin, an antibiotic drug, in serum. Measurements obtained by this device are used in the diagnosis and treatment of vancomycin overdose and in monitoring the level of vancomycin to ensure appropriate therapy.

(b) *Classification*. Class II.

## 21 CFR Ch. I (4–1–05 Edition)

### PART 864—HEMATOLOGY AND PATHOLOGY DEVICES

#### Subpart A—General Provisions

Sec.

864.1 Scope.

864.3 Effective dates of requirement for pre-market approval.

864.9 Limitations of exemptions from section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act).

#### Subpart B—Biological Stains

864.1850 Dye and chemical solution stains.

864.1860 Immunohistochemistry reagents and kits.

#### Subpart C—Cell and Tissue Culture Products

864.2220 Synthetic cell and tissue culture media and components.

864.2240 Cell and tissue culture supplies and equipment.

864.2260 Chromosome culture kit.

864.2280 Cultured animal and human cells.

864.2360 Mycoplasma detection media and components.

864.2800 Animal and human sera.

864.2875 Balanced salt solutions or formulations.

#### Subpart D—Pathology Instrumentation and Accessories

864.3010 Tissue processing equipment.

864.3250 Specimen transport and storage container.

864.3260 OTC test sample collection systems for drugs of abuse testing.

864.3300 Cytocentrifuge.

864.3400 Device for sealing microsections.

864.3600 Microscopes and accessories.

864.3800 Automated slide stainer.

864.3875 Automated tissue processor.

#### Subpart E—Specimen Preparation Reagents

864.4010 General purpose reagent.

864.4020 Analyte specific reagents.

864.4400 Enzyme preparations.

#### Subpart F—Automated and Semi-Automated Hematology Devices

864.5200 Automated cell counter.

864.5220 Automated differential cell counter.

864.5240 Automated blood cell diluting apparatus.

864.5260 Automated cell-locating device.

864.5300 Red cell indices device.

864.5350 Microsedimentation centrifuge.

864.5400 Coagulation instrument.

## Food and Drug Administration, HHS

Pt. 864

864.5425 Multipurpose system for in vitro coagulation studies.  
864.5600 Automated hematocrit instrument.  
864.5620 Automated hemoglobin system.  
864.5680 Automated heparin analyzer.  
864.5700 Automated platelet aggregation system.  
864.5800 Automated sedimentation rate device.  
864.5850 Automated slide spinner.  
864.5950 Blood volume measuring device.

### Subpart G—Manual Hematology Devices

864.6100 Bleeding time device.  
864.6150 Capillary blood collection tube.  
864.6160 Manual blood cell counting device.  
864.6400 Hematocrit measuring device.  
864.6550 Occult blood test.  
864.6600 Osmotic fragility test.  
864.6650 Platelet adhesion test.  
864.6675 Platelet aggregometer.  
864.6700 Erythrocyte sedimentation rate test.

### Subpart H—Hematology Kits and Packages

864.7040 Adenosine triphosphate release assay.  
864.7060 Antithrombin III assay.  
864.7100 Red blood cell enzyme assay.  
864.7140 Activated whole blood clotting time tests.  
864.7250 Erythropoietin assay.  
864.7275 Euglobulin lysis time tests.  
864.7280 Factor V Leiden DNA mutation detection systems.  
864.7290 Factor deficiency test.  
864.7300 Fibrin monomer paracoagulation test.  
864.7320 Fibrinogen/fibrin degradation products assay.  
864.7340 Fibrinogen determination system.  
864.7360 Erythrocytic glucose-6-phosphate dehydrogenase assay.  
864.7375 Glutathione reductase assay.  
864.7400 Hemoglobin A<sub>2</sub> assay.  
864.7415 Abnormal hemoglobin assay.  
864.7425 Carboxyhemoglobin assay.  
864.7440 Electrophoretic hemoglobin analysis system.  
864.7455 Fetal hemoglobin assay.  
864.7470 Glycosylated hemoglobin assay.  
864.7490 Sulfhemoglobin assay.  
864.7500 Whole blood hemoglobin assays.  
864.7525 Heparin assay.  
864.7660 Leukocyte alkaline phosphatase test.  
864.7675 Leukocyte peroxidase test.  
864.7695 Platelet factor 4 radioimmunoassay.  
864.7720 Prothrombin consumption test.  
864.7735 Prothrombin-proconvertin test and thrombotest.  
864.7750 Prothrombin time test.  
864.7825 Sickle cell test.

864.7875 Thrombin time test.  
864.7900 Thromboplastin generation test.  
864.7925 Partial thromboplastin time tests.

### Subpart I—Hematology Reagents

864.8100 Bothrops atrox reagent.  
864.8150 Calibrator for cell indices.  
864.8165 Calibrator for hemoglobin or hematocrit measurement.  
864.8175 Calibrator for platelet counting.  
864.8185 Calibrator for red cell and white cell counting.  
864.8200 Blood cell diluent.  
864.8500 Lymphocyte separation medium.  
864.8540 Red cell lysing reagent.  
864.8625 Hematology quality control mixture.  
864.8950 Russell viper venom reagent.

### Subpart J—Products Used In Establishments That Manufacture Blood and Blood Products

864.9050 Blood bank supplies.  
864.9100 Empty container for the collection and processing of blood and blood components.  
864.9125 Vacuum-assisted blood collection system.  
864.9145 Processing system for frozen blood.  
864.9160 Blood group substances of nonhuman origin for in vitro diagnostic use.  
864.9175 Automated blood grouping and antibody test system.  
864.9185 Blood grouping view box.  
864.9195 Blood mixing devices and blood weighing devices.  
864.9205 Blood and plasma warming device.  
864.9225 Cell-freezing apparatus and reagents for in vitro diagnostic use.  
864.9245 Automated blood cell separator.  
864.9275 Blood bank centrifuge for in vitro diagnostic use.  
864.9285 Automated cell-washing centrifuge for immuno-hematology.  
864.9300 Automated Coombs test systems.  
864.9320 Copper sulfate solution for specific gravity determinations.  
864.9400 Stabilized enzyme solution.  
864.9550 Lectins and protectins.  
864.9575 Environmental chamber for storage of platelet concentrate.  
864.9600 Potentiating media for in vitro diagnostic use.  
864.9650 Quality control kit for blood banking reagents.  
864.9700 Blood storage refrigerator and blood storage freezer.  
864.9750 Heat-sealing device.  
864.9875 Transfer set.

AUTHORITY: 21 U.S.C. 351, 360, 360c, 360e, 360j, 371.

## Subpart A—General Provisions

### § 864.1 Scope.

(a) This part sets forth the classification of hematology and pathology devices intended for human use that are in commercial distribution.

(b) The identification of a device in a regulation in this part is not a precise description of every device that is, or will be, subject to the regulation. A manufacturer who submits a premarket notification submission for a device under part 807 may not show merely that the device is accurately described by the section title and identification provisions of a regulation in this part, but shall state why the device is substantially equivalent to other devices, as required by § 807.87.

(c) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.

(d) Guidance documents referenced in this part are available on the Internet at <http://www.fda.gov/cdrh/guidance.html>.

[52 FR 17732, May 11, 1987, as amended at 69 FR 12273, Mar. 16, 2004]

### § 864.3 Effective dates of requirement for premarket approval.

A device included in this part that is classified into class III (premarket approval) shall not be commercially distributed after the date shown in the regulation classifying the device unless the manufacturer has an approval under section 515 of the act (unless an exemption has been granted under section 520(g)(2) of the act). An approval under section 515 of the act consists of FDA's issuance of an order approving an application for premarket approval (PMA) for the device or declaring completed a product development protocol (PDP) for the device.

(a) Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a device that has been found substantially equivalent to such a device, has an approval under section 515 of the act FDA must promulgate a regulation under section 515(b) of the act requiring such approval, except as provided in paragraph (b) of this section. Such a regulation under section 515(b) of the

act shall not be effective during the grace period ending on the 90th day after its promulgation or on the last day of the 30th full calendar month after the regulation that classifies the device into class III is effective, whichever is later. See section 501(f)(2)(B) of the act. Accordingly, unless an effective date of the requirement for premarket approval is shown in the regulation for a device classified into class III in this part, the device may be commercially distributed without FDA's issuance of an order approving a PMA or declaring completed a PDP for the device. If FDA promulgates a regulation under section 515(b) of the act requiring premarket approval for a device, section 501(f)(1)(A) of the act applies to the device.

(b) Any new, not substantially equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed that has been substantially altered, is classified by statute (section 513(f) of the act) into class III without any grace period and FDA must have issued an order approving a PMA or declaring completed a PDP for the device before the device is commercially distributed unless it is reclassified. If FDA knows that a device being commercially distributed may be a “new” device as defined in this section because of any new intended use or other reasons, FDA may codify the statutory classification of the device into class III for such new use. Accordingly, the regulation for such a class III device states that as of the enactment date of the amendments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.

[52 FR 17732, May 11, 1987]

### § 864.9 Limitations of exemptions from section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act).

The exemption from the requirement of premarket notification (section 510(k) of the act) for a generic type of class I or II device is only to the extent that the device has existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of in vitro diagnostic devices, only to the